Cigna’s Evernorth division is rolling out a rebate-free model for its pharmacy benefit manager, Express Scripts—meaning one of the industry’s “Big Three” is moving away from the oft-criticized approach. More: Cigna's Express Scripts set to shift away from PBM rebates
read moreInnovent’s Eli Lilly-partnered mazdutide, a GLP-1/glucagon (GCG) dual receptor agonist, displayed broader effects on patients’ blood glucose levels and weight loss than Novo’s leading GLP-1 semaglutide in a head-to-head trial. More: Innovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes,
read morePaving the way for the label update were results from the phase 3 Zenith trial, which was stopped early due to a positive efficacy signal. More: Merck nabs updated FDA label for soon-to-be-blockbuster Winrevair Source: fierce
read more
$25m milestone payment supports pipeline progress in neurodegenerative disease research More: Evotec and Bristol Myers Squibb advance neuroscience partnership Source: News
read moreAstraZeneca and Organon have been found in serious breach of the U.K.’s pharma code, with a watchdog ruling that both companies brought discredit on the industry. More: UK watchdog slams AstraZeneca, Organon for marketing breaches Source: fierce
read more
Qureight’s imaging platform validated in peer-reviewed study More: AI model Vascul8 offers new hope for pulmonary vascular disease patients Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals